Low sTWEAK concentrations were associated with more inadequate cardiometabolic risk in patients with type 2 diabetes and obesity, and this can be explained by the ability of sTWEAK to antagonize in vitro TNF-α activity22. The gene discussed is TNF; the disease is Obesity.